Mifoglame (Sitagliptin)

Sitagliptin selectively blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones GLP‑1 and GIP. By preventing this breakdown, the drug raises circulating incretin levels, which in turn stimulate insulin release and suppress glucagon in a glucose‑dependent manner, helping to lower blood glucose after meals and overall.

The prescribed dose of Mifoglame is determined by the treating physician based on the patient’s renal function, glycaemic targets, and concomitant therapies. The prescriber will specify the exact strength and frequency, and patients should follow the written instructions without alteration.

Safety of sitagliptin in pregnancy and lactation has not been firmly established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its insulin‑stimulating effect is glucose‑dependent. Unlike insulin, it is administered orally and does not require injection. It is often used as an add‑on therapy to metformin or other agents when glycaemic control remains suboptimal.

Mifoglame tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack or bottle. Protect them from excess moisture, heat and direct sunlight to maintain potency throughout the shelf‑life.

Mifoglame is taken by mouth, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically advised.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe allergic reactions such as angio‑edema or Stevens‑Johnson syndrome, and joint pain that may be disabling. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or unexplained severe arthralgia.

Mifoglame is contraindicated in individuals with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for patients with severe renal impairment, a history of pancreatitis, or those who are pregnant or breastfeeding unless the benefits outweigh the risks.